Hypothesis

Transient synchronization of cells in S‑phase during chemical reprogramming will exploit replication‑coupled chromatin disassembly to achieve more complete erasure of donor‑cell epigenetic signatures and normalize metabolic functions, thereby closing the rejuvenation gap observed with current chemical cocktails.

Rationale

Recent work shows that epigenetic resetting during OSKM reprogramming depends on S‑phase chromatin opening: blocking DNA replication with aphidicolin reduces accessibility at OCT4/SOX2/KLF4 sites, and fast‑cycling subpopulations display eight‑fold higher pluripotency locus accessibility [3]. Chemical partial reprogramming reduces senescence markers but increases ROS and halves proliferation, indicating a metabolic gap that persists despite epigenetic changes [4]. If chromatin disassembly is the rate‑limiting step for erasing aging‑associated DNA methylation, then forcing a larger fraction of cells into S‑phase should increase the efficiency of demethylation at tissue‑specific loci and allow the metabolic reset to keep pace with epigenetic changes.

Prediction

1. Epigenetic metric – iPSCs generated from aged fibroblasts under chemical cocktails plus a brief (2‑4 h) CDK2 inhibitor release (to synchronize at G1/S) will show a ≥30 % reduction in residual methylation at donor‑cell‑specific CpG islands compared with chemical reprogramming alone (measured by bisulfite sequencing) [1].
2. Chromatin accessibility – ATAC‑seq will reveal a ≥2‑fold increase in signal at OCT4/SOX2/KLF4 enhancers in synchronized conditions, matching the accessibility seen in fast‑cycling OSKM‑reprogrammed cells [3].
3. Metabolic read‑outs – ROS levels (MitoSOX fluorescence) and proliferation rates (EdU incorporation) will be indistinguishable from those of fully OSKM‑reprogrammed iPSCs, while senescence markers (SA‑β‑gal, p21) remain low [4].
4. Functional outcome – Differentiation bias toward the original fibroblast lineage (quantified by lineage‑specific qPCR after directed differentiation) will be reduced to baseline embryonic stem‑cell levels, indicating erasure of aging memory [2].
5. Safety – Teratoma formation in immunodeficient mice will not increase relative to OSKM iPSCs, confirming that the protocol does not push cells toward pluripotency‑associated tumorigenicity.

Experimental Design

• Cell source: Passaged human fibroblasts from donors >70 years old.
• Conditions: (A) Chemical reprogramming cocktail alone (baseline); (B) Same cocktail + 2 h CDK2 inhibitor (e.g., CVT‑313) washout to release cells into S‑phase; (C) Full OSKM transduction as positive control.
• Timing: Synchronization pulse applied at 24 h after cocktail addition, when MET is initiating.
• Readouts: Collect samples at 48 h, 96 h, and day 14 for methylation, ATAC‑seq, ROS, proliferation, senescence, and differentiation assays.
• Analysis: Compare each metric across conditions using ANOVA with post‑hoc Tukey; falsify the hypothesis if synchronized condition fails to show significant improvement over baseline in at least two of the three domains (epigenetic, chromatin, metabolic).

Implications

If proven, this approach would define replication timing as a tunable lever for complete multiparameter rejuvenation, bridging the gap between epigenetic reprogramming and metabolic restoration without the tumorigenic risk of full pluripotency. It also provides a clear, falsifiable roadmap for optimizing chemical rejuvenation strategies in aging research.